Pembrolizumab
Cold Chain RequiredFDA Approved
Description
Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of certain cancers. It works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing PD-1 mediated inhibition of the immune response.
Indications & Therapeutic Use
Anaplastic thyroid cancer, Transitional cell carcinoma of the corpus uteri
Global Availability (3 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Pembrolizumab
| Generic Name | Pembrolizumab |
| Brands | 1 brand available |
| Active Ingredient | Pembrolizumab |
| Drug Class | Anaplastic thyroid cancer |
| Manufacturer | Merck |
| Dosage Forms | Injection |
| Medical Code | L01FF02 |
| Orphan Status | No |
| Cold Chain | Required |
| Reg. Status | FDA Approved |
| Countries | 3 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations4 Validated Nodes